Castle Biosciences, Inc. (CSTL)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
CSTL Chart
People also search for
Castle Biosciences, Inc. (CSTL) Q1 2026 Earnings Call Transcript
Castle Biosciences, Inc. (CSTL) Q1 2026 Earnings Call Transcript
Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Beats Revenue Estimates
Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to a loss of $0.2 per share a year ago.
Castle Biosciences: Buying The Remaining DecisionDx-Melanoma Upside
Castle Biosciences, Inc. is positioned as a leader in precision cancer diagnostics, notably with DecisionDx-Melanoma, offering scalable, clinically validated solutions. CSTL reported strong Q4/FY2025 revenue growth and robust cash reserves but faces a projected EPS decline in 2026 as it invests aggressively in growth and commercialization. DecisionDx-Melanoma stands out as a de-risked, durable growth driver with high clinical utility, workflow integration, and payer support, targeting a large and growing melanoma market.
Castle Biosciences, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 53 | $1,082.45 | $1,280.48 | $198.03 | 18.29% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 3,248 | $66,135.09 | $78,471.68 | $12,336.59 | 18.65% |
| SN Stephanie Nee HARBOR CAPITAL ADVISORS Inc. | 25,614 | $654,045.52 | $618,834.24 | -$35,211.28 | -5.38% |
 Jeff Ameen Spire Wealth Management | 50 | $1,001 | $1,208 | $207 | 20.68% |
 Joseph Castro Nuveen LLC | 522,127 | $10.61M | $12.12M | $1.51M | 14.18% |
Castle Biosciences, Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Mark Massaro BTIG | 40.86 | $741.54 | $981.37 | $239.83 | 32.34% |
Castle Biosciences, Inc. (CSTL) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Castle Biosciences, Inc. ever had a stock split?
Castle Biosciences, Inc. Profile
| Professional Services Industry | Industrials Sector | Derek J. Maetzold CEO | NASDAQ (NMS) Exchange | 14843C105 CUSIP |
| US Country | 883 Employees | - Last Dividend | - Last Split | 25 Jul 2019 IPO Date |
Overview
Castle Biosciences, Inc. is a pioneering molecular diagnostics company that focuses primarily on devising testing solutions to aid in the diagnosis and effective treatment of various conditions, including dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health disorders. The company leverages its expertise in gene expression profiling and pharmacogenomics to develop tests that can significantly influence patient management decisions, particularly in the areas of skin cancer, gastroenterology, and mental health. Established in 2007, Castle Biosciences is headquartered in Friendswood, Texas, where it continues to innovate in the field of molecular diagnostics, emphasizing its commitment to improving patient outcomes by providing pivotal information that can guide treatment decisions.
Products and Services
- DecisionDx-Melanoma: This is a risk stratification gene expression profile (GEP) test designed to ascertain the metastasis risk in patients diagnosed with invasive cutaneous melanoma. The test aids in the identification of patients at high risk of metastasis, which can have significant implications for treatment planning and patient management.
- DecisionDx-SCC: A proprietary GEP test that serves as a risk stratification tool for patients with cutaneous squamous cell carcinoma. This test provides critical information regarding the likelihood of disease progression, assisting in the customization of patient care plans.
- MyPath Melanoma: Targeted at patients with melanocytic lesions that are hard to diagnose, MyPath Melanoma helps in delineating benign nevi from malignant melanoma, aiding clinicians in making informed decisions about patient management.
- TissueCypher: This spatial omics test is designed to predict the future development of high-grade dysplasia and/or esophageal cancer in patients with Barrett's esophagus, including those with non-dysplastic, indefinite for dysplasia, or low-grade dysplasia. The test plays a crucial role in early detection and prevention strategies.
- DecisionDx-UM: A proprietary risk stratification GEP test for patients with uveal melanoma, DecisionDx-UM predicts the risk of metastasis, guiding clinical management and surveillance strategies for patients diagnosed with this rare but aggressive form of melanoma.
- IDgenetix: This pharmacogenomic test is designed to assist in guiding drug treatment decisions for a range of mental health conditions, including major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. By analyzing genetic variations that affect drug response, IDgenetix helps to personalize medication regimens for improved efficacy and reduced side effects.
